A recent study on five patients with AD and five age-matched healthy controls demonstrated longitudinal changes in tau pathology in patients with AD that was consistent with post-mortem observation of tau pathology in the different stages of AD and correlated with the rate of cognitive decline in patients with AD [170]. The gene discussed is MAPT; the disease is Alzheimer disease.